Japan Sepsis Diagnostics Market Size & Outlook, 2022-2030
Japan sepsis diagnostics market, 2018-2030 (US$M)
Related Markets
Japan sepsis diagnostics market highlights
- The Japan sepsis diagnostics market generated a revenue of USD 45.6 million in 2022 and is expected to reach USD 96.5 million by 2030.
- The Japan market is expected to grow at a CAGR of 9.8% from 2023 to 2030.
- In terms of segment, blood culture media was the largest revenue generating product in 2022.
- Assay Kits & Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Sepsis diagnostics market data book summary
| Market revenue in 2022 | USD 45.6 million |
| Market revenue in 2030 | USD 96.5 million |
| Growth rate | 9.8% (CAGR from 2022 to 2030) |
| Largest segment | Blood culture media |
| Fastest growing segment | Assay Kits & Reagents |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Blood Culture Media, Assay Kits & Reagents, Software |
| Key market players worldwide | BD, BioMerieux SA, Thermo Fisher Scientific Inc, Danaher Corp, Roche Holding AG ADR, Luminex, Koninklijke Philips NV, Bruker Corp, Cepheid, Immunexpress |
Other key industry trends
- In terms of revenue, Japan accounted for 4.5% of the global sepsis diagnostics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan sepsis diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 77.2 million by 2030.
Blood culture media was the largest segment with a revenue share of 39.04% in 2022. Horizon Databook has segmented the Japan sepsis diagnostics market based on instruments, blood culture media, assay kits & reagents, software covering the revenue growth of each sub-segment from 2018 to 2030.
Japan faces a significant burden of sepsis, largely due to its aging population and increasing prevalence of chronic diseases. Sepsis remains a leading cause of mortality in Japanese hospitals, emphasizing the urgent need for effective diagnostic solutions.
Approval and launch of novel sepsis diagnostic tests, coupled with supportive reimbursement scenarios, are expected to support market growth. For instance, in August 2018, Sysmex Corporation, a Japanese healthcare company, launched its new HISCL Presepsin Assay Kit for Sepsis Testing.
In March 2024, the Tokyo Metropolitan Government issued a warning as cases of Streptococcal Toxic Shock Syndrome (STSS), a severe and rare bacterial infection, have surged. This year, reported cases in Tokyo have already surpassed half of last year’s total, reaching 88 infections in the capital alone, with a national tally of 517 cases.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sepsis Diagnostics Market Scope
Sepsis Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan sepsis diagnostics market size, by product, 2018-2030 (US$M)
Japan Sepsis Diagnostics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
